First Hawaiian Bank boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 31.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,358 shares of the company’s stock after buying an additional 2,022 shares during the quarter. First Hawaiian Bank’s holdings in Johnson & Johnson were worth $1,014,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. Financial Gravity Wealth Inc. bought a new position in shares of Johnson & Johnson in the first quarter worth approximately $105,000. FNY Investment Advisers LLC bought a new position in shares of Johnson & Johnson in the second quarter worth approximately $117,000. Princeton Capital Management LLC bought a new position in shares of Johnson & Johnson in the first quarter worth approximately $141,000. Smart Portfolios LLC bought a new position in shares of Johnson & Johnson in the first quarter worth approximately $150,000. Finally, Live Your Vision LLC boosted its position in shares of Johnson & Johnson by 58.3% in the second quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock worth $172,000 after purchasing an additional 502 shares during the period. Institutional investors own 66.67% of the company’s stock.
A number of equities analysts have weighed in on JNJ shares. Goldman Sachs Group upgraded shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research report on Thursday, July 12th. Sanford C. Bernstein started coverage on shares of Johnson & Johnson in a research report on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 price target for the company. Credit Suisse Group set a $151.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Friday, July 13th. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Finally, Jefferies Financial Group set a $145.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Sunday, July 15th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company. Johnson & Johnson currently has an average rating of “Hold” and an average price target of $143.91.
JNJ stock opened at $133.87 on Friday. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.32. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $370.70 billion, a PE ratio of 18.34, a P/E/G ratio of 2.19 and a beta of 0.70.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 17th. The company reported $2.10 EPS for the quarter, topping the consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The firm had revenue of $20.83 billion for the quarter, compared to the consensus estimate of $20.39 billion. During the same quarter in the previous year, the firm earned $1.83 earnings per share. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post 8.14 EPS for the current year.
In other news, COO Michael E. Sneed sold 29,000 shares of the business’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the transaction, the chief operating officer now owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now directly owns 25,725 shares in the company, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is currently owned by insiders.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.